A medicine begins as an argument. A molecule might slow a tumor, quiet an immune system or replace a broken gene. But before a regulator accepts that argument, someone has to turn it into a controlled human experiment - recruit the right patients, train the sites, ship the kits, watch for safety signals, reconcile the data and explain every deviation. Medpace occupies that long, precarious distance between promising science and persuasive evidence.
The Cincinnati company is a contract research organization, or CRO. Its customers are biotech, pharmaceutical and medical-device companies that hire it to run some or all of a clinical-development program. The label sounds administrative. The work is closer to directing an orchestra whose musicians are spread across hospitals, laboratories, time zones and regulatory regimes, while the score is still being annotated.
By June 2026, Medpace employed roughly 6,500 people across 46 countries. It produced $2.53 billion in revenue in 2025, up 20 percent from the year before, and ended that year with a $3.03 billion backlog. In the second quarter of 2026 alone, revenue was $707.3 million. Those numbers describe a substantial public company. The more revealing figure is the customer mix: in 2025, 82 percent of net revenue came from small biopharmaceutical companies.
The company-sized hole inside a biotech
An emerging biotech may be built around a dozen gifted scientists and one valuable asset. What it usually does not have is a standing army of clinical monitors, statisticians, safety physicians, regulatory writers, laboratory technicians, imaging readers and country experts. Hiring all of them before knowing whether the drug works would be slow and ruinously expensive. Splitting the study among specialist vendors creates a different risk: every handoff becomes a place where context gets lost.
Medpace sells the missing organization. It can help shape a protocol, identify countries and sites, start the study, monitor conduct, manage patient recruitment, collect and clean data, analyze results, prepare regulatory submissions and oversee drug safety. Around that core sit central and bioanalytical laboratories, an imaging core lab, ECG and cardiac-safety services, clinical supplies, logistics, and an 85-bed Phase I unit in Cincinnati for early studies.
One trial, five linked systems
This is the problem Medpace is built to solve: a clinical trial is both a scientific test and a supply chain for trustworthy information. A late shipment can become a missing sample. A poorly selected site can become an enrollment delay. An inconsistent scan can muddy an endpoint. A protocol that ignores local practice can fail before the first participant signs a consent form. Each mistake consumes time, and for a young biotech, time is also cash runway.
The product is not the pill. It is evidence that can survive inspection.The CRO business in one sentence
Fewer seams, more memory
Medpace's answer is its full-service model. Rather than assemble a fresh federation of subcontractors, it emphasizes teams working within common processes and technology. Its central labs are wholly owned. Its imaging and cardiac groups connect to the wider trial. Its clinicians are aligned by therapeutic area, from oncology and cardiology to metabolic disease, neuroscience, infectious disease, rare disease, cell and gene therapy, radiopharmaceuticals and devices.
The software layer is ClinTrak, an in-house platform refined over more than 20 years. It combines clinical trial management, electronic data capture, randomization and inventory, laboratory information, imaging and patient-reported outcomes. A sponsor can see operational and scientific signals in one place instead of waiting for competing systems to exchange files. IntelliPACE applies historical and external data to feasibility and site selection. The technology is not sold as a freestanding SaaS product; it strengthens the service engagement.
That distinction matters. A generic dashboard can display that recruitment is late. A therapeutically experienced team should recognize why: perhaps the eligibility criteria exclude the patients a site actually treats, or the standard of care in one country makes participation unattractive. Medpace's pitch is that data, medical judgment and operating responsibility belong in the same room.
The anti-roll-up
August Troendle founded Medpace in 1992 after serving as an FDA medical review officer and managing the development of lipid-altering drugs at Sandoz. He remains chairman and chief executive. That continuity is unusual in any public company, more so in a CRO market reshaped by consolidation. IQVIA, ICON, Parexel, PPD, Fortrea, Syneos Health and Labcorp compete through various combinations of scale, data, laboratories and specialized services.
Medpace describes its own path as organic growth. The boast is less romantic than it sounds. Clinical studies can run for years, so changes in systems, reporting lines or staff can be disruptive. A company built on common training and homegrown processes can argue that it carries less integration scar tissue than an acquisitive rival. It also retains more control over the mundane but decisive links between kit production, sample testing, imaging review and the final database.
When the customer's problem contains costly handoffs, integration can be a product feature. Medpace did not merely add adjacent services. It connected them with shared data, incentives and accountability.
There are trade-offs. Full-service contracts concentrate responsibility, but they also concentrate customer dependence. Sponsors may prefer specialist vendors, functional-service staffing or internal teams. Trials can be canceled when financing tightens or data disappoints. Backlog is not guaranteed revenue. And no operating model can repeal biology: an impeccably run study can still show that a therapy does not work.
Medpace's business model absorbs those uncertainties without taking ownership of the drug. It is paid for services as work is performed, generally through fixed-fee or unit-based contracts plus reimbursed pass-through costs. The sponsor keeps the asset's enormous upside and its scientific risk. Medpace takes execution risk - budgets, staffing, timelines and quality - across a portfolio of programs.
The logistics of credibility
The company's recent investments show where that execution gets physical. In 2025, Medpace expanded its Leuven, Belgium logistics hub to more than 4,000 square meters. The site can hold more than 300,000 sample-collection kits and produce nearly 500,000 kilograms of dry ice a year. Its Shanghai central laboratory more than doubled to 1,945 square meters. Microbiology capabilities expanded in Cincinnati and Shanghai.
These details are not glamorous, which is why they are useful. A temperature-sensitive tube moving from a clinic to a laboratory is a tiny container of scientific value. It needs the correct kit, label, handling, customs paperwork, storage and chain of custody. Lose any one of those and the trial may lose a data point that cannot be recreated. The same logic applies to an image read consistently across hospitals or an adverse event reported quickly across borders.
Recognition from research sites offers another view of the machinery. In 2025, Medpace won the Society for Clinical Research Sites' CRO Eagle Award, based on feedback from nearly 2,000 sites, and received a WCG Pinnacle Award for professionalism and communication. Sites experience CROs at ground level: contracts, payments, startup requests, technology and the speed of an answer when a patient is waiting. Their approval is not proof of every claim, but it is evidence from the people asked to make protocols real.
Clinical trials cannot be hurried. They can, however, be spared a remarkable amount of avoidable waiting.Where Medpace fits in the market
A toll road for the biotech century
Medpace sits between invention and commercialization. It is downstream from universities, drug-discovery platforms and venture-backed laboratories; upstream from regulatory approval, manufacturing and the pharmacy shelf. When capital flows into biotech and the number of complex molecules grows, more sponsors need clinical infrastructure. Cell therapies, radiopharmaceuticals, rare-disease programs and precision imaging add scientific promise, but also operational choreography.
For customers, the practical question is not whether Medpace can make a weak drug succeed. It cannot. The question is whether it can help a sound program reach an answer sooner, with fewer preventable errors and evidence that regulators, investors and physicians can trust. That can mean choosing sites with the right patients, designing measurable endpoints, finding a safety signal early or simply giving a small sponsor a current view of its own study.
For Medpace, the opportunity is equally plain. Young biotechs will continue to invent assets before they build global operating departments. Large drugmakers will continue to outsource selected programs. Every trial will keep generating data, samples, scans and decisions that must agree. The company's durable advantage, if it has one, is institutional memory: what thousands of earlier site starts, shipments, reads and database locks teach the next team.
The public sees a new medicine as a product. Medpace sees the enormous temporary organization required to prove it. That organization appears for a few years, crosses several borders, asks sick people to participate, and then dissolves into a submission. Building it repeatedly - carefully, measurably and without losing the plot - is the quiet business behind the breakthrough.